Potassium competitive acid blocker
Package with 30 coated tablets
Disponible en:
Each coated tablet contains:
Tegoprazan 50.0 mg
Excipients: q.s.
KI-CAB is indicated for:
- Treatment of erosive gastroesophageal reflux disease
- Treatment of non-erosive gastroesophageal reflux disease
- Treatment of gastric ulcer
- Combination antibiotic therapy for the eradication of Helicobacter pylori in patients with peptic ulcer and/or chronic atrophic gastric disease.